Alana Hippensteele is lead editor at Pharmacy Times®, Contemporary Clinic, and Pharmacy Times Oncology Edition®. She has a master's in Critical Theory and Creative Research from Pacific Northwest College of Art and a bachelor's degree in English and Art History. She has worked as an English instructor at Temple University and held editorial positions at American Cleaning & Hygiene and Tin House.
NLA 2025: ApoC3 Inhibitors Show Promise Across a Spectrum of Hypertriglyceridemic Disorders
May 31st 2025Emerging therapies targeting apolipoprotein C-III (ApoC3) are demonstrating significant promise in lowering triglycerides and reducing cardiovascular risk for patients with severe hypertriglyceridemia and rare disorders, such as familial chylomicronemia syndrome.
Read More
NLA 2025: The Complementary Roles of ANGPTL3 and ANGPTL4 in Lipid Regulation and Therapy
May 30th 2025Sander Kersten, PhD, discusses the distinct roles of ANGPTL3 and ANGPTL4 in lipid metabolism, their interactions with key enzymes, the therapeutic potential of targeting these pathways in lipid-lowering strategies, and important considerations for pharmacists counseling patients on emerging ANGPTL-targeted therapies.
Read More
Helping Patients Navigate GLP-1 Therapy: Practical Strategies for Pharmacists
May 30th 2025Katherine H. Saunders, MD, DABOM, explores the role of pharmacists in supporting long-term weight management with GLP-1 therapies, including strategies for counseling on lifestyle interventions, managing adverse effects, and ensuring patients receive individualized, evidence-based care.
Read More
ASCO 2025: Pretreatment DPYD Testing for Fluoropyrimidines Can Improve Patient Safety and Lower Cost
May 29th 2025Two abstracts from the American Society of Clinical Oncology (ASCO) annual meeting demonstrate that pretreatment DPYD genotyping improves the safety and cost-effectiveness of fluoropyrimidine chemotherapy, with oncology pharmacists playing a pivotal role in implementing and optimizing genotype-guided dosing strategies.
Read More
HER2 and HER3 in NSCLC: The Latest ADC Data and NCCN Guideline Updates
May 29th 2025Corrine Stahura, PharmD, and Sophia Gilardone, PharmD, BCOP, discuss recent clinical trial data and evolving guideline recommendations for HER2- and HER3-directed antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC), highlighting differences in efficacy, safety, and patient selection criteria.
Read More
ASCO 2025: Real-World Strategies for DPYD-Variant–Guided Fluoropyrimidine Dosing
May 28th 2025Grace Nguyen, PharmD, BCPS, provides real-world experiences with DPYD genotype-guided fluoropyrimidine dosing, highlighting how pharmacist-led interventions and tailored dose adjustments can help mitigate toxicity risks and optimize treatment in variant carriers.
Read More
Pharmacist Perspectives on ADC-Associated Toxicity in NSCLC Treatment
May 28th 2025Corrine Stahura, PharmD; and Sophia Gilardone, PharmD, BCOP, discuss how patient- and treatment-related factors influence the risk of severe toxicity with antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC).
Read More
Health Care Is a Human Right: A Roundtable on Values, Visibility, and the Work Ahead
In this roundtable, 3 pharmacy faculty members reflect on how shifting federal priorities and the defunding of research initiatives have impacted their work, communities, and careers—while highlighting the power of resilience, solidarity, and reimagined academic impact in advancing public health equity.
Read More
HER2 and HER3 ADCs in Focus: Clinical Pearls for Managing Emerging Toxicities
May 27th 2025Corrine Stahura, PharmD; and Sophia Gilardone, PharmD, BCOP, discuss the distinct adverse effect profiles of HER2- and HER3-targeted antibody-drug conjugates—particularly the risk and management of interstitial lung disease—and offer practical guidance based on clinical trial data and treatment protocols.
Read More
Christian John Lillis on C diff, Public Health, and the Role of Pharmacists
May 24th 2025Christian John Lillis reflects on key insights from the 2025 Peggy Lillis Foundation C diff Summit, highlighting the critical role of pharmacists in infectious disease care, persistent challenges in patient outcomes, and the need for renewed investment in public health infrastructure and policy.
Read More
C diff, Community, and Public Trust: Insights From Christian John Lillis
May 23rd 2025Christian John Lillis discusses the 2025 Peggy Lillis Foundation C diff Summit, emphasizing the enduring need for community-building among survivors, the importance of sustained public health advocacy, and the growing urgency to defend federal health agencies amid political and institutional uncertainty.
Read More
The Mentorship Model: Cultivating Resilience and Leadership in Palliative Care Pharmacy
May 22nd 2025At the 2025 SPPCP Virtual Conference, Carolyn Hall, PharmD, BCPS, and Maria Felton Lowry, PharmD, BCPS, BCGP, presented a comprehensive and practical framework for pharmacy professionals to build effective, adaptable mentorship relationships.
Read More
NCCN Adds Naxitamab as Category 2A Recommendation for High-Risk Neuroblastoma
May 18th 2025Naxitamab-gqgk has been added as a Category 2A recommendation in the updated National Comprehensive Cancer Network (NCCN) guidelines for high-risk neuroblastoma, reflecting growing consensus on its role in treating relapsed or refractory disease.
Read More
Cynthia Ryan, PharmD, BCPS, discusses practical, evidence-based strategies for pharmacists to identify, prevent, and manage dermatologic toxicities associated with cancer therapies, emphasizing interdisciplinary collaboration, patient education, and proactive supportive care to improve adherence and outcomes.
Read More
Can Low-Dose Naltrexone Fill the Gaps in Palliative Pain Management?
May 12th 2025Emma Murter, PharmD, MPH, and Madison N. Irwin, PharmD, BCPS, discuss the potential role of low-dose naltrexone in managing chronic pain in palliative care, highlighting its anti-inflammatory properties, limited adverse effects, and current evidence gaps—particularly in comparison to traditional opioids and adjuvant analgesics.
Read More
Psilocybin at the Crossroads: Regulatory Barriers and the Pharmacist’s Role in Palliative Innovation
May 6th 2025Abigail Thomas, PharmD, and Lee A. Kral, PharmD, discuss the evolving role of psilocybin-assisted therapy in palliative care, highlighting current evidence, safety concerns, and how pharmacists can guide patient selection, manage drug interactions, and support education as the therapy moves closer to clinical use.
Read More
Pharmacist-Led Care in Palliative Settings: Using Anticholinergics Thoughtfully and Compassionately
May 5th 2025Diana Violanti, PharmD, and Pamela S. Moore, PharmD, BCGP, discuss the nuanced use of anticholinergic agents for managing terminal secretions at end of life, highlighting practical considerations, timing, safety concerns such as delirium, and the limited yet evolving evidence supporting their role in palliative care.
Read More
As evidence grows for psilocybin-assisted therapy’s effectiveness in treating mental health and addiction, efforts are increasingly focused on ensuring equitable access—particularly for underserved communities disproportionately affected by systemic barriers and public health crises.
Read More
Jonas Congelli, RPh, discusses how limited distribution networks and medically integrated pharmacies can improve access, continuity, and quality of oncology care—particularly in underserved areas—while addressing systemic barriers posed by traditional distribution models and pharmacy benefit managers.
Read More
Real-World Data, Real-Time Decisions: AI at the Front Lines of Oncology
May 2nd 2025Ravi Parikh, MD, MPP, FACP, discusses how artificial intelligence is transforming oncology pharmacy by accelerating drug development, enhancing clinical decision-making, supporting value-based care, and raising critical questions about ethics, regulation, and data integrity.
Read More
Tariffs, Tensions, and Transformation: Pharmacy at a Crossroads
May 2nd 2025Jacinda Abdul-Mutakabbir, PharmD, MPH, AAHIVP, discusses how looming tariffs, vaccine misinformation, and rising drug costs are straining public health pharmacy efforts, while also sparking new opportunities for innovation, collaboration, and community-centered care amid uncertainty.
Read More
AACR 2025: Liposomal Annamycin May Enhance Chemotherapy Efficacy Across Hematologic and Solid Tumors
May 1st 2025Liposomal annamycin demonstrates broad synergistic activity with multiple FDA-approved chemotherapies across hematologic and solid tumors in preclinical models, offering a promising and safer combination strategy for resistant and high-risk cancers.
Read More
Precision Oncology in Focus: ctDNA's Role in Colon Cancer Management
April 30th 2025Sasha Watson, PharmD, BCOP, discusses the emerging role of circulating tumor DNA (ctDNA) in colon cancer, highlighting its potential to enhance precision oncology by improving early detection, guiding adjuvant therapy decisions, and monitoring disease recurrence and treatment resistance.
Read More